Video
Dr. Saad on Patients With mCRPC Eligible for 6-Doses of Radium-223
Author(s):
Fred Saad, MD, professor and chairman of Urology, director of GU Oncology, the University of Montreal Hospital Centers, discusses results of an analysis that examined which patients with metastatic castration-resistant prostate cancer are able to receive the recommended 6-doses of radium-223 dichloride (Xofigo).
Fred Saad, MD, professor and chairman of Urology, director of GU Oncology, the University of Montreal Hospital Centers, discusses results of an analysis of the Expanded Access Program that examined which patients with metastatic castration-resistant prostate cancer (mCRPC) are able to receive the recommended 6 doses of radium-223 dichloride (Xofigo).
Outcomes were observed in patients who received the full 6- or 5-cycle regimen versus those who received less than 4 cycles of radium-223, Saad explains. Patients who received more doses had an improvement in overall survival.
Patients who were healthier earlier in the course of the disease had lower PSA levels, had mild or no levels of pain, and had high hemoglobin levels were more likely to receive the full 6-cycle regimen of radium-223. These results also demonstrate that practitioners should treat patients with radium-223 earlier in their treatment course versus in a later setting.
